Labcorp
Prezzo: 266.16Società e modello di business
Labcorp is a leading healthcare company that provides comprehensive laboratory services and diagnostic solutions. Its core offerings include clinical laboratory testing, drug development services, and genomic testing. The company operates in two major segments: Labcorp Diagnostics and Labcorp Drug Development. Major revenue sources stem from clinical testing services for healthcare providers and pharmaceutical companies, as well as from its extensive portfolio of laboratory tests and clinical trials.
Profilo di investimento
The investment profile of Labcorp is more aligned with value investors, given its stable revenue generation and modest dividend yield. The stock may appeal to those seeking consistent performance rather than aggressive growth, reflecting a balanced approach to risk and potential returns.
Metriche fondamentali (sperimentale)
- EPS (TTM) — utile per azione degli ultimi 12 mesi, $
- 11.37 OK
- Ricavi QoQ — crescita dei ricavi trimestre su trimestre
- 0.6% ≈
- Sorpresa EPS
- 3.0% in linea
- Volatilità 20g
- 1.1% stabile
- Rendimento dividendo
- 1.1% moderato ultima data ex-dividendo: 2026-05-29
Traccia in portafoglio
Grafico prezzo
| Data | Prima | Dopo | Motivo |
|---|---|---|---|
| 2026-06-10 00:48 | Mantieni | Compra | Strong performance and solid fundamentals support growth potential. |
| 2026-05-24 02:44 | Vendi | Mantieni | Mixed performance; cautious outlook amid market conditions. |
| 2026-05-16 02:42 | Mantieni | Vendi | Weak momentum and fundamentals raise significant risk. |
| Data | Analista | Action | Target | Prezzo allora |
|---|---|---|---|---|
| 2026-05-01 12:49 | Robert W. Baird | Target alzato | 332 → 334 | 255.97 |
| 2026-04-08 13:14 | Evercore ISI | Target alzato | 280 → 300 | 274.72 |
| 2026-02-24 11:40 | Piper Sandler | Target alzato | 270 → 300 | 285.3 |
Ancora nulla